The financial report is eye-catching! Revenue growth of Kangchen pharmaceutical industry in the first half of the year exceeded 70%

[China Pharmaceutical network enterprise news] Kangchen Pharmaceutical Co., Ltd announced its mid-term performance in 2017 on Thursday, and the sales growth continued However, behind the eye-catching financial report is Kangchen Pharmaceutical Group's 20-year accumulation and technological pursuit of excellence On the 20th anniversary of the group, Kangchen has worked hard to create a bigger blueprint for the health industry The growth rate of the industry slows down and the gross profit decreases Kangchen strives for progress in stability, and the financial report is eye-catching As an industry with sustained demand growth, the development trend of the pharmaceutical industry is very stable However, with the continuous introduction of medical policies, medical insurance, drug price reform and other factors lead to the slowdown in the growth rate of the pharmaceutical industry and the reduction of gross profit According to the 2017 blue book on the development of China's pharmaceutical market: in the first half of 2017, the sales volume of China's pharmaceutical terminal market was 803.7 billion yuan, up 7.8% year-on-year, and the overall growth rate slowed down In addition, with the full implementation of the two vote policy for drugs in 2018, the industry concentration of various sectors of the pharmaceutical industry will further improve, and the pharmaceutical reform will enter the deep water area Kangchen Pharmaceutical Co., Ltd yesterday announced its mid-term performance in 2017, and the sales growth continued In the first half of the year, the revenue was 769 million yuan (RMB, the same below), an increase of 70.3% over the same period of last year; net profit was 185 million yuan, an increase of 27.1% over the same period of last year; ebitad was 305 million yuan, an increase of 48.4% over the same period of last year The core product group has obvious advantages, with strong performance growth momentum classified by product series The sales revenue of the company's main kidney series products increased by 10.1% year on year, among which the leading product Niaoduqing granules is still the locomotive of sales growth, occupying the market share of Nephrology oral modern Chinese patent medicine As for medical imaging contrast agents, sales revenue decreased by 11.2% year-on-year, but it still occupied the top three of the domestic MRI contrast agent market While the sales of other drugs increased by 792.7% year-on-year, of which, the sales revenue of women's and children's products dextran iron oral liquid increased by 87.2% year-on-year, the sales revenue of bone setting fluid series products increased by 28.2% year-on-year, and the sales revenue of liver and gall series products increased by 33.4% year-on-year Capital integration has brought outstanding performance, and it is worth mentioning that Yulin pharmaceutical and its subsidiaries, the affiliated company of Kangchen pharmaceutical industry, have also performed well Yulin pharmaceutical achieved sales revenue of 264 million yuan in the period, an increase of 25.5% over the same period last year Yulin Pharmaceutical Group completed the capital increase and share expansion of 300 million yuan and issued new stock certificates to all shareholders It has passed the tga-gmp certification in Australia for the eighth time in a row, laying a solid foundation for expanding the overseas market Behind the eye-catching financial report is Kangchen Pharmaceutical Group's 20-year accumulation and technological pursuit of excellence On the occasion of the group's 20th anniversary, Kangchen has worked with one heart and one mind to forge ahead to create a bigger blueprint for the health industry Kangchen Pharmaceutical Co., Ltd is committed to R & D and innovation, and has established the "kidney disease drug research center" invested by enterprises in China so far The company's product, Niaoduqing, completed evidence-based medicine research in 2016 and systematic biology research in 2017 New drugs for diabetic nephropathy have passed the examination and approval of major new drug creation projects of the 13th five year plan of the state, and obtained 1.84 million subsidies In the near future, the self-developed product of the contrast agent plate, iodophor, has been on the market Since its listing in 2013, the group has achieved the goal of "three years to rebuild a Kangchen", with revenue, profit and asset growth of more than 100% Talking about the future development, the head of Kangchen pharmaceutical said: in order to enhance the return of shareholders and human resources as well as the loyalty of customers, and constantly innovate in products and services, the company firmly moves towards a high-quality growth state In the second half of 2017, Kangchen will continue to take product R & D and market development as the development basis, adhere to the 6 + 1 product strategy, improve business management, continue to enrich product lines, create large varieties, continue to improve brand awareness and influence, expand group business through strategic investment / acquisition, strengthen R & D capabilities, actively carry out external cooperation, continue to expand distribution network Strengthen market promotion, cultivate and recruit key talents that affect business development, and strive to bring more brilliant achievements Original title: outstanding performance of financial report! Revenue growth of Kangchen pharmaceutical industry in the first half of the year exceeded 70%!